Life Sciences News | BioTuesdays by Kilmer Lucas IR

Developments

Hepion completes first cohort enrollment in Phase 2 trial of CRV431

Hepion Pharmaceuticals (NASDAQ:HEPA) enrolled the last patient in the 75 mg cohort of its Phase 2 ‘AMBITION’ clinical trial evaluating CRV431 for the treatment of non-alcoholic steatohepatitis (NASH). “We are pleased to...

November 10, 2020

Developments

Monopar Therapeutics gets new patents for Validive

Monopar Therapeutics (NASDAQ:MNPR) received additional patents for its Phase 2b/3 clinical-stage candidate, Validive. Monopar is developing Validive for the prevention of chemoradiation-induced severe oral mucositis in...

November 9, 2020

Developments

Corbus Pharma updates Phase 3 systemic sclerosis study results

Corbus Pharmaceuticals (NASDAQ:CRBP) updated data from its Phase 3 study of lenabasum for the treatment of systemic sclerosis. Systemic sclerosis is an autoimmune disease characterized by inflammation and fibrosis...

November 9, 2020

Developments

Entera Bio completes enrollment in Phase 2 osteoporosis trial

Entera Bio (NASDAQ:ENTX) completed enrollment in its Phase 2 trial evaluating EB613 for the treatment of osteoporosis. EB613 is an orally delivered human parathyroid hormone designed to build bone in osteoporosis...

November 9, 2020

Executive Moves

ObsEva names Brian O’Callaghan as CEO

Brian O’Callaghan ObsEva (NASDAQ:OBSV) appointed Brian O’Callaghan as CEO, effective Dec. 1. He succeeds ObsEva’s co-founder, Ernest Loumaye, M.D., Ph.D., who is retiring from his role as CEO but will remain a...

November 9, 2020

Markets

Raymond James starts Perimeter Medical Imaging at OP; PT $3 (Canadian)

Raymond James initiated coverage of Perimeter Medical Imaging AI (TSXV:PINK) with an “outperform” rating and price target of $3 (Canadian). The stock closed at $2.19 on Nov. 6. Perimeter is commercializing its Optical...

November 9, 2020

Markets

William Blair starts Codiak BioSciences at OP

William Blair launched coverage of Codiak BioSciences (NASDAQ:CDAK) with an “outperform” rating based on the potential of the company’s novel exosome platform and clinical readouts over the next six-to-nine months...

November 9, 2020

Markets

Stifel starts AVEO Pharma at buy; PT $9

Stifel initiated coverage of AVEO Pharmaceuticals (NASDAQ:AVEO) with a “buy” rating and price target of $9. The stock closed at $5.66 on Nov. 6. AVEO is focused on the development and commercialization of targeted...

November 9, 2020

Developments

IntelGenx reports montelukast effect on neurological aging published in peer-reviewed journal

IntelGenx (TSXV:IGX; OTCQB:IGXT) reported that the peer-reviewed International Journal of Clinical Pharmacy published a study on montelukast’s effect on aging. IntelGenx is currently conducting a Phase...

November 9, 2020

Executive Moves

Marizyme names Neil Campbell as president and CEO

Marizyme (NASDAQ:MRZM) appointed Neil Campbell, Ph.D., as CEO, replacing executive chairman James Sapirstein, who has been the company’s interim CEO since September 2020. Dr. Campbell currently serves as chairman of...

November 6, 2020

Developments

Humanigen reports positive interim data from Phase 3 COVID-19 trial

Humanigen (NASDAQ:HGEN) reported positive interim results from its Phase 3 trial evaluating lenzilumab in hospitalized COVID-19 patients. Lenzilumab is an antibody that targets granulocyte-macrophage colony-stimulating...

November 6, 2020

Markets

SVB Leerink cuts Neovasc PT to $2 from $6

SVB Leerink slashed its price target for Neovasc (NASDAQ:NVCN) to $2 from $6, citing timing uncertainty for a U.S. launch of the company’s Reducer stent for percutaneous treatment of refractory angina. The stock closed...

November 6, 2020

Hepion completes first cohort enrollment in Phase 2 trial of CRV431

Monopar Therapeutics gets new patents for Validive

Corbus Pharma updates Phase 3 systemic sclerosis study results

Entera Bio completes enrollment in Phase 2 osteoporosis trial

ObsEva names Brian O’Callaghan as CEO

Raymond James starts Perimeter Medical Imaging at OP; PT $3 (Canadian)

William Blair starts Codiak BioSciences at OP

Stifel starts AVEO Pharma at buy; PT $9

IntelGenx reports montelukast effect on neurological aging published in peer-reviewed journal

Marizyme names Neil Campbell as president and CEO

Humanigen reports positive interim data from Phase 3 COVID-19 trial

SVB Leerink cuts Neovasc PT to $2 from $6

General

More